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cultured in vitro. The artificially produced tissue masses exhibited normal
morphology and cell function. Organ tissue cultured includes small intestine
epithelial and mesenchymal cells.
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CULTURED NORMAL MAMMALIAN TISSUE AND PROCESS
ORIGIN OF THE INVENTION
The invention described herein was made in the perfor-
mance of work under a NASA contract and is subject to the
5 provisions of Section 305 of the National Aeronautics and
Space Act of 1958, Public Law 85-568 (72 Stat. 435; 42 U.S.C.
2457).
RELATED PATENTS AND APPLICATIONS
The present case is a continuation in part of United
i0 States Patent Application Serial Number 07/939,791 filed
September 3, 1992 entitled "Three-Dimensional Coculture
Process" which is a continuing application of Serial Number
07/317,931 filed March 2, 1989 entitled "Three-Dimensional
Coculture Process" now U.S. Patent No. 5,153,132 issued
15 October 6, 1992 which is a continuation-in-part of Serial No.
317,776 filed March 2, 1989 entitled "Three Dimensional Cell
and Tissue Assembly Process" now U.S. Patent No. 5,155,034
issued October 13, 1992 which is a continuation-in-part of
Serial No. 213,588, filed June 30, 1988, now Patent No.
5,026,650, issued June 25, 1991 entitled "Horizontally
Rotated Cell Culture System with a Coaxial Tubular Oxygena-
tor" and Serial No. 213,559 filed June 30, 1988, now Patent
No. 4,988,623 issued January 29, 1991 entitled "Rotating Bio-
Reactor Cell Culture Apparatus" and Serial No. 625,345 filed
December ii, 1990 now U.S. Patent No. 5,153,131, issued
October 6, 1992 entitled "High Aspect _Reactor Vessel and
Method of Use", all of which are specifically incorporated as
if fully set forth herein.
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FIELD OF THE INVENTION
The invention relates to production of functional three
dimensional mammalian tissue from a culture of normal cells
in fluid media.
5 BACKGROUND OF THE INVENTION
The culturing of mammalian cells presents many challeng-
es as compared to bacteria, yeast and molds. Bacterial-type
cells have tougher outer cell walls and can be manipulated
without injuring the cells during culture, whereas mammalian
i0 cells are delicate and cannot withstand stress. Bacterial-
type cells are not organized into functional tissue groups
with cell differentiation or organization as seen in higher
life forms such as mammals.
Mammalian tissue can be grouped into three general
15 categories of (i) organ tissue (2) structural tissue and (3)
blood producing tissue. Mammalian tissue is composed of
aggregates of cells that share a functional interrelationship
in order to have tissue growth. Mammalian tissue is composed
of different types of cells characterized by different
20 morphology and immunochemical properties. Cellular differen-
tiation in mammals involves complex interactions in which
cell membrane junctions, extracellular matrices such as
basement membrane and ground substances. Soluble signals
produced and shared among the cells play an important role.
25 Study of normal mammalian tissue, however, has been
limited because of lack of adequate in vitro culture systems
that product tissue of sufficient size and functionality. In
contrast, tumor cells are by their nature easier to grow in
vitro, possess abnormal growth characteristics and do not
30 behave like normal cells in their interaction with neighbor-
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ing cells. Sutherland, "Cell and Environment Interactions in
Tumor Microregions: The Multicell Spheroid Model", Science,
Vol. 240, pp. 177-240, 8 April 1988. Different culture
methods for normal and abnormal mammalian cells have been
5 used. Elaborate culture systems for normal mammalian cells
have been developed in an attempt to grow normal tissue.
A variety of different cells and tissues, such as bone
marrow, skin, liver, pancreas, mucosal epithelium, adeno-
carcinoma and melanoma, have been grown in culture systems to
i0 provide three dimensional growth in the presence of a pre-
established stromal support matrix. U.S. Patent No. 4,963,4-
89, Three-Dimensional Cell and Tissue Culture System,
Naughton, et al., Oct. 16, 1990; U.S. Patent No. 5,032,508,
Three-Dimensional Cell and Tissue Culture System, Naughton,
15 et al., July 16, 1991. A biocompatible, non-living material
formed into a three dimensional structure is inoculated with
stromal cells. In some cases, the three dimensional struc-
ture is a mesh pre-coated with collagen. Stromal cells and
the associated connective tissue proteins naturally secreted
20 by the stromal cells attach to and envelop the three dimen-
sional structure. The interstitial spaces of the structure
become bridged by the stromal cells, which are grown to at
least subconfluence prior to inoculating the three dimension-
al stromal matrix with tissue-specific cells.
25 Normal mammalian tissue has been grown for limited
periods of time as two-dimensional monolayers on gelled
substrate or other surface for anchoring the cells. Adult
colonic epithelial cells have been found to be more difficult
to culture than fetal colonic epithelial cells. Buset et al.
30 "Defining Conditions to Promote the Attachment of Adult Human
Colonic Epithelial Cells", In Vitro Cell. & Dev. Biol., Vol.
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23. No. 6 pp. 403-412 ( June 1987). To mimic a more normal
environment using monolayer culture, cocuitures were prepared
using two cell types, often with a "feeder layer" of fibro-
5 blasts or other cells to supply the primary cells with
nutrients and other factors difficult to incorporate into a
substrate and to provide the cellular interaction believed to
be necessary for the production of differentiated tissue.
Reid et al., "Culturing Hepatocytes and Other Differentiated
Cells", _, Vol. 4, No. 3, pp. 548-559 (1984); Haake
i0 et al. "Retention of Differentiated Characteristics in Human
Fetal Keratinocytes In Vitro", In Vitro Cell. & De v" Biol.,
Vol. 25 No. 25 pp. 592-600 (July 1989). Also, monolayers
"conditioned,, with fibroblast cells have been used to impart
into the substrate the soluble growth factors for epithelial
15 cells. Kabalin et al. "Clonal Growth of Human Prostatic
Epithelial Cells Is Stimulated by Fibroblasts,,, The Prostate,
Vol. 14, pp. 251-263 (1989). Monolayers do not produce a
three dimensional tissue, but rather a two-dimensional spread
of cells. Often the cells developed by monolayer culture and
20 coculture become undifferentiated and lack normal function.
Three dimensional in vitro models of differentiated
tissue have been produced, however, the cells often do not
demonstrate normal cellular activity. Embryonic avian
skeletal muscle cells have been grown in vitro on expandable
25 membranes which are gradually and substantially, continuously
stretched to simulate the mechanical stimulation of cells
experienced in vivo. U.S. Patent No. 4,940,853,
Method for Growing Tissue Specimens in Vitro, Vadenburgh,
July i0, 1990. The expandable support membrane supports
development of three dimensional structures which more
closely resemble tissue grown in vivo, however, normal
3O
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independent cellular activity was not identified. Addi-
tionally, three dimensional human mammary epithelial cells
have been grown in collagen. U.S. Patent No. 5,026,637,
Soule, et al., June 25, 1991. However, the cells, under the
5 culture conditions, did not undergo terminal differentiation
and cell senescence, but rather were "immortal" in that they
retained the capacity to divide forever. Thus, normal
cellular activity and naturalization was not observed.
The study of the organ systems exemplifies the complex
i0 interrelationship of neighboring cells in mammalian tissue
necessary for normal three dimensional tissue growth.
Mammalian organ systems have been studied to determine the
relationship of the cell types that make up the organ as well
as their effects on each other. Studies on normal tissue
15 differentiation have indicated an important interaction
between epithelial cells and mesenchymal cells and the
production and differentiation of the cells from fibroblasts.
Kaye et al., "The Colonic Pericryptal Fibroblast Sheath:
Replication, Migration, and Cytodifferentiation of a Mesen-
20 chymal Cell System in Adult Tissue" Gastroenteroloc_v, Vol.
60. No. 4, pp. 515-536 (1971). Furthermore, small intestine
tissue is exemplary of organ tissue types with epithelial
cells with functional brush borders and organized columnar
cells associated with mesenchymal cells. Other organs have
25 similar organization. Small intestine tissue has physical
support in vivo so that the tissue forms crypts which
increase the surface area of the organ. In addition to the
crypt formation in vivo, there are also immunocytochemical
markers for particular cell types with normal functionality
30 as well as cell types that are in developmental phases to
produce functional organ tissue.
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Immunochemical properties further characterize normal
cells types and tissue. Keratin, vimentin and Factor VIII
antibodies detect epithelial, fibroblastic and endothelial
cells respectively. Villin is a cytoske!etal protein only
5 found in epithelial cells from the small intestine and colon.
The angioblast marker is present in certain precursor
endothelial cells, particularly dividing cells. Sucrase is
an enzyme found in the epithelial cell brush border of the
small intestine. Basement membrane and extracellular matrix
i0 components such as laminin, fibronectin, Collagen IV, and
proteoglycan are associated with ordering of tissue and
cellular polarity. Basement membrane and extracellu!ar
matrix development has been related to epithelia!-mesenchymal
development and differentiation. All these components are
15 necessary for normal tissue growth.
Culture of normal or neoplastic small intestine epithe-
lium as large-scale three dimensional configurations has not
been shown with routinely used in vitro culture technology.
Chantret et al., "Epithelial Polarity, Villin Expression and
20 Eterocytic Differentiation of Cultured Human Colon Carcinoma
Cells: A survey of Twenty Cell Lines" Cancer Res., Vol. 48,
pp. 1936-1942 ( April i, 1988). Factors that control
proliferation and differentiation in the gastrointestinal
tract remain largely unknown. Corps et al., "Stimulation of
25 Intestinal Epithelial Cell Proliferation in Culture by Growth
Factors in Human and Ruminant Mammary Secretions" J. Endocr.,
Vol. 113, pp. 285-290 (3 Nov. 1986); O'Loughlin et al.,
"Effect of Epidermal Growth Factor on Ontogeny of the
Gastrointestinal Tract" Am. J. Phvsiol., Vol. 249, pp. G674-
30 G678 (8 July 1985); Blay et al., "Contradistinctive Growth
Responses of Cultured Rat Intestinal Epithelial Cells to
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Epidermal Growth Factor Depending on Cell Population Density"
J. of Cell. Phvsiol., Vol. 129, pp.343-346 (15 July 1986).
Cartilage tissue is exemplary of normal structural
tissue. Attempts have been made to encourage cartilage
5 formation in vitro by culturing chondrocytes. Typical
culture durations achieved in the more successful instances
range from I0 days to 30 days, the 30-day point being a
transition towards static culture or cellular degeneration
and death. The success achieved to date has had limited 3-
I0 dimensionality. Typical cell culture methodologies include
isolating chondrocytes from various articular surfaces and
plating the isolated chondrocytes as a monolayer in a T-
flask. Various manipulations were then utilized to encourage
chondrocyte expansion and differentiation, and the deposition
15 of proteoglycan into the interstitial matrices. These
maneuvers include various growth factor augmentations, an
effort to emulate in situ conditions. The extent to which
the cells can be maintained in situ is on the order of tens
of years as seen in the normal adult. Conversely, in
20 standard cell culture the extent which cells can be main-
tained in a growth phase or a normal static maintenance phase
is on the order of 22 days. It has been demonstrated that
multiple cell-surface receptors exist that are important in
cellular growth and differentiation, and extracellular matrix
25 formation. Cell surface receptors are labile to destructive
cell surface sheer.
Cartilage cells were reportedly cultured for 13 months
using a solid substrate in conventional culture vessels.
U.S. Patent No. 4,757,017 Cheung et al., July 12, 1988. The
30 solid substrate was a porous calcium compound. Multilayer
7
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cell growth was observed and the cells maintained theirphenotype.
Bone marrow has been grown using conventional monolayer
cell culture technique. Human bone marrow cell culture
5 technique. Human bone marrow cell production declines over
time in monolayer culture. Naughton et. al. disclosed a bone
marrow culture system in co-culture with stromal cells or
mixtures of cell types on a three dimensional support. U.S.
Patent No. 4,963,489. The three dimensional support was
i0 coated by cells such as fetal fibroblasts over a collagen
layer on a mesh support.
Mammalian tissue has been grown in bioreactors providing
low shear from abnormal cell types such as tumor cells or
cocultures with normal and tumor cells. Goodwin et al.,
15 "Morphological Differentiation of Colon Carcinoma Cell Lines
HT-29 and HT-29K in Rotating-Wall Vessels,,, In Vitro Cell.
Dev. Biol. Vol. 28A, pp. 47-60, January 1992. The bioreactor
designs are disclosed in U.S. Patent Nos. 4,988,623;
5,026,650 and 5,153,131. Co-culture of tumor and normal
20 cells in solid-state culture has been reported as shown in
U.S. Patent No. 4,352,887 to Reid et al. issued October 5,
1982. However, since tumor or abnormal cells grow under
conditions that normal cells cannot tolerate, the growth of
non-normal cells does not predict success for normal mammali-
25 an culture under the same or similar culture conditions.
There are many potential uses of artificially produced
tissue for different mammalian systems. For example, small
intestine tissue can be used as a model for the molecular and
clinical treatment of diseases such as inflammatory bowel
30 disease (Crohn's, ulcerative colitus), malabsorptive syn-
dromes (short-gut syndrome), numerous infectious diseases and
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tumors of the small bowel. The tissue can be a model for the
therapeutic trials prior to in vivo experimentation. However
cultures longer than 7 weeks have been difficult to achieve,
since crypt cells are unable to survive standard culture
5 regimens, and two-dimensional organ cultures do not support
the de novo assembly of stroma and its contribution to
epithelial cell growth. Shamsuddin, "Colon Organ Culture as
a Model for Carcinogenesis", Colon Cancer Cells, Moyer and
Poste, Eds. Academic Press, Inc. 1990.
I0 Also, a mammalian structural tissue such as a cartilage
model of high fidelity is important in clinical studies.
There are numerous maladies associated with cartilage,
including but not limited to knee-joint injuries, back
injuries, articular-surface injuries, inflammatory diseases
15 such as arthritis and temporal-mandibular joint disease.
Beyond the diseases are the natural processes of maturation
through puberty and the geriatric inability to repair and
maintain articular surfaces. A tissue model would be
beneficial for the analyses and development of therapeutic
20 protocols. Moreover, these models become essential in
tailoring pharmaceuticals, i.e.; non-steroidal anti-inflamma-
tories where the pharmaceutical may actually become detrimen-
tal to the chondrocyte by way of degradation into secondary
metabolites.
25 The artificial production of functional blood tissue
such as normal bone marrow could be used in patients in need
of bone marrow replacement which have lost the ability to
produce the tissue. The tissue could be grown from a sample
and transplanted back to the patient. Also, bone marrow
30 material can be transplanted into a non-autologous recipient.
9
MSC-21984-I PATENT APPLICATION
SUMMARY OF THE INVENTION
Aggregates of normal mammalian cells have been produced
in vitro for each of the three major tissue groups. The cell
aggregates exhibited three dimensional tissue growth and
5 functional interrelationship by cell to cell contact.
Functional cells with normal morphology have been produced
for organ, structural and blood producing tissues. Cell
function was in some cases confirmed immunohistochemically by
antibodies specific to particular cellular components
i0 characterizing cell types.
The aggregates were produced under "microgravity culture
conditions" which can be microgravity or simulated micro-
gravity. Simulated microgravity was created in unit gravity
by controlling the horizontal rotation of a culture vessel
15 containing normal mammalian cells, culture matrix and
completely filled with culture media. In the preferred
process a horizontally rotating wall culture vessel produced
the simultaneous conditions of (i) collocation of cells and
culture matrix with similar or differing sedimentation
20 properties in a similar spatial region, (2) freedom for three
dimensional spatial orientation of tissues formed by the
culturing of the cells and (3) low shear and essentially no
relative motion of the culture environment with respect to
the walls of the culture vessel. The culture conditions
25 included mass transfer under microgravity conditions with
exchange of nutrients for metabolic waste and appropriate gas
exchange in the culture system.
The process for producing the normal mammalian tissue is
particularly unique in that the resultant product is normal
30 tissue of a size of 2 millimeters and larger. The size of
the tissue cultured is significant because assembly of three
i0
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dimensional masses of this size is not possible without the
complex functional interrelationship of the normal mammalian
cells.
Functional three dimensional organ tissue masses have
5 been produced artificially from an inoculum of predominantly
normal differentiated epithelial cells and predominantly
normal differentiated mesenchymal cells. The epithelial and
mesenchymal cells were preferably disassociated prior to
introduction into the culture vessel. The epithelial and
i0 mesenchymal cells were introduced in a vessel with a culture
matrix preferably of generally spherical microcarriers.
Tissue engineering was achieved by selected introduction of
the mesenchymal cells and culture matrix for a preselected
culture period prior to transfer of epithelial cells to the
15 culture vessel.
A three dimensional normal organ tissue mass grew in
association with the culture matrix having functional
epithelial cells and functional mesenchymal cells. Also, the
tissue developed cells immunochemically characterized as
20 functional endothelial precursor cells in significantly
greater numbers than were present in the initial inoculum.
The organ tissue mass also developed cells immunochemically
characterized as functional angioblasts and cells that were
immunochemically characterized as functional epithelial cell
25 brush borders. Organized columnar cells were clearly
visible. The developing organ tissue included cells immunoc-
hemically characterized as basement membrane components. As
the tissue masses grew anchored to microcarriers they were
joined with cord-like structures of fibroblasts covered by
30 epithelial cells.
ii
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A preferred fluid media for mammalian organ tissue
culture is a MEM (minimum essential medium) base with a tri-
sugar supplement and fetal bovine serum. The preferred tri-
sugar supplement is selected from mixtures of fructose,
5 galactose and glucose.
The organ tissue can be initiated by various normal
mammalian organ cells including skin, small intestine,
pancreas, liver, colon, and endocrine gland. Predominantly
normal terminally differentiated cells were able to revert to
!0 a state that allowed interaction of a growing cellular mass
capable of normal organ tissue evolution without using non-
differentiated cells and without using cell types such as
tumor cells that have abnormal cell growth characteristics.
Artificially produced structural tissue has been
15 produced in microgravity culture conditions from normal
structural tissue. The three dimensional structural tissue
mass developed with functional chondrocytes and stromal cells
with tissue calcification. The tissue exhibited matrix
deposition including cells immunochemically characterized as
producing Type IV, Type IX and Type X collagen. The struc-
tural tissue is cultured in a vessel at microgravity condi-
tions as described herein with a culture matrix. A preferred
culture matrix was generally spherical microcarriers. An
initial inoculum used in the process to produce the structur-
al tissue mass was nonhuman embryonic cartilage cells
disassociated prior to transfer to the culture vessel.
Three dimensional mammalian blood tissue of normal
origin has been produced artificially. The bone marrow
tissue was prepared from normal bone marrow cells. The
inoculum from the bone marrow include pleuripotential stem
cells, fully matured white blood cells and red blood cells.
2O
25
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The bone marrow cells were transferred into a culture vessel
with fluid culture media and culture matrix. Microgravity
culture conditions as described herein were maintained while
three dimensional tissue growth was achieved. The culture
5 matrix can be disc-shaped. The bone marrow can be encased in
stromal-like matrices and introduced into the vessel. Also,
culture matrix of Type I rat tail collagen and biopolymers
can be used.
Relatively large normal mammalian three dimensional
i0 tissue masses were cultured using microgravity culture
conditions. The ability of the cells to grow into large
aggregates supports the functional relationship achieved by
cell to cell contact of normal cells. The process and normal
tissue of this invention can be used advantageously as an in
15 vitro produced mammalian product.
2O
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BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a view at 200X magnification of a three
dimensional artificial normal organ tissue mass.
Figure 2 is a photograph of artificial normal organ
tissue at 200X magnification.
Figure 3 is a photograph of artificial normal organ
tissue at 500X magnification.
Figure 4 is a photograph of artificial normal organ
tissue at 1500X magnification.
Figure 5 is a photograph of artificial normal organ
tissue at 50X magnification.
Figure 6 is a photograph of artificial normal structured
tissue at 500X magnification.
13
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Figure 7 is a photograph of artificial normal structural
tissue at 1500X magnification.
Figure 8 is a photograph of artificial normal structural
tissue at 200X magnification.
Figure 9 is a photograph of artificial normal structural
tissue at 1500X magnification.
Figure i0 is a schematic drawing of the blood producing
tissue cells and microcarriers.
DETAILED DESCRIPTION OF THE INVENTION
i0 Aggregates of cells from the three major tissue groups
were cultured in vitro. The artificially produced tissue
masses exhibited normal morphology and cell function.
Examples of organ tissue, structural tissue and blood tissue
are described below.
15 The artificially produced mammalian organ tissue was
generated from normal small intestine epithelial and mesen-
chymal cells. Human small intestine epithelial and mesenchy-
mal cells were obtained from normal organs of patients,
predominantly organ transplant donors, with no evidence of
20 disease. The cells were then propagated in culture. The
cells were initiated and propagated in M3 media supplemented
with 2% fetal bovine serum (FBS), designated M3:2, for
epithelial cells or with 10% FBS, designated M3:I0, for
mesenchymal cells. M3 medium is a complex base medium
supplemented with many growth factors and nutrients including
L-Broth (tryptone broth), bovine pituitary extract, hydrocor-
tizone, essential and non-essential amino acids, pentagas-
trin, epidermal growth factor, transferrin, selenium, and
insulin. Moyer, "Methods for Propagation and Characteriza-
25
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tion of Human GI and Other Cells for Study of HIV," J. Tiss.
Cult. Meth., Vol. 13, pp. 107-116 (1991).
All cell cultures were grown in a Forma humidified CO 2
incubator with 95% air, 5% CO 2, and constant atmosphere at a
5 temperature of 37°C. Normal mesenchymal cells were passaged
as required by enzymatic dissociation with a solution of 0.1%
Trypsin, 0.1% EDTA, for 15 minutes at 37°C. After incubation
with the appropriate enzymes, the cells were centrifuged at
800 x G for i0 minutes in Corning conical 15-ml centrifuge
I0 tubes. The cells were then resuspended in fresh medium and
diluted into Corning T-flasks with 25 ml of fresh growth
medium. Small intestine epithelial cells were passaged by
dilution at a 1:2 ratio into fresh M3:2 medium in T-flasks.
Cultures of epithelial cells were derived from the ileum and
15 jejunum of three male donors (22-35 years of age). Mesenchy-
mal cells were obtained from the submucosa of five donors (4
males, 17-27 years old, and a 2-month-old female).
Normal mesenchymal cells were removed from T-75 flasks
by enzymatic digestion, washed once with calcium- and
20 magnesium-free PBS (CMF-PBS), and assayed for viability by
Trypan Blue dye exclusion (GIBCO). Cells were held on ice in
fresh growth medium until inoculation. In the preferred
process the primary inoculum introduced into the culture
vessel was 2 x 105 mesenchymal cells/ml in a 125-mi volume
25 with 5 mg/ml Cytodex-3 microcarrier beads (Pharmacia, Pisca-
taway, NJ). Cytodex-3 microcarriers were Type I, collage-
coated dextran beads, 175 microns in diameter. After the
primary inoculumwas prepared for seeding, it was transferred
to a culture vessel filled with culture media and cultured at
30 microgravity conditions.
15
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In a preferred method the microgravity conditions were
simulated in unit gravity by a horizontal rotating wall
vessel (RWV). A preferred RWV bioreactor is described in
U.S. Patent No. 5,026,650 to Schwarz et al. issued June 25,
5 1991 and is incorporated by reference herein. The rotation
of the culture vessel (bioreactor) was controlled to produce
the simultaneous conditions of (!) collocation of cells and
culture matrix with similar or differing sedimentation
properties in a similar spatial region, (2) freedom for three
i0 dimensional spatial orientation of tissues formed by the
culturing of the cells and (3) low shear and essentially no
relative motion of the culture environment with respect to
the walls of the culture vessel. The trajectory of the cell
aggregates was determined. The speed of the rotation of the
15 culture vessel was increased if the cell aggregates fell
excessively inward and downward on the downward side of the
rotational cycle and excessively outward and insufficiently
upward on the upgoing side of the rotational cycle to prevent
wall impact. The rotation of the culture vessel was de-
20 creased in response to excessive accumulation of tissue
aggregation near the outer wall of the culture vessel so as
not to restrict three dimensional growth. As the tissue
aggregates grow the rotation was adjusted to obtain minimal
collision frequency and intensity.
25 The culture media used in the RWV can be varied. A I:i
mixture of M3:2 medium and standard minimal essential medium-
alpha (MEM-alpha) (GIBCO) supplemented with 10% FBS was used.
A preferred media designated GTSF-2 was found to meet the
growth requirements of the system without the need for unique
30 growth factors and other complex components found in other
media including M3:2. The GTSF-2 media is a trisugar-based
16
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medium with glucose, galactose and fructose supplemented with
6% FBS. A preferred formulation for GTSF-2 media is listed
in Table 1 below. The pH was adjusted to 7.4 with IN NaOH.
17
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MEM-alpha supplemen-
ted with 2.25gm/L
NaHCO_
L-15
NaHC%
HEPES
Folic acid
0.5% Nicotinic acid
Bactopeptone
I-inositol
Fructose
Galactose
D-Glucose
300mM L-Glutamine
Gentamycin
Fungizone
Insulin-transferrln_
sodium-solenite
Fetal bovine serum
TABLE 1
Tri-Sugar Based
GTSF-2
Concentration
Medium
400ml (40%)
600ml (60%)
1.35gm/liter
3.0gm/liter
6.667_g/liter
0.667ml/liter
0.6gm/liter
0.024_./liter
0.13gm/liter
0.25gm/liter
1.0gm/liter
10ml/liter
iml/liter
2ml/liter
5ml/liter
60ml (6%)
Source/O.rder or
GIBCO/430-1900EB
GIBCO/430-1300EB
Sigma/S-5761
Research Or-
ganics/6003H-2
Sigma/F-8758
Sigma/N-4126
Difco/0118-01
Sigma/I-5125
Sigma/F-3510
Sigma/G-5388
Sigma/G-5250
Sigma/G-5763
GIBCO/600-5750AD
GIBCO/600-5295AE
Sigma/I-1884
Hyclone/A-llll-L
18
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The primary inoculum of mesenchymal cells was allowed to
grow for a minimum of 2-3 days before the medium was changed.
Then 2 x l0 S epithelial cells/ml were added prepared as
described above for the mesenchymal cells. The organ tissue
5 can be bioengineered to develop desired patterns of cell
layering by preselecting the introduction of the epithelial
cells into the culture vessel. Also, the cells can be
introduced essentially simultaneously into the vessel to
produce normal organ tissue.
i0 Culture conditions included mass transfer with exchange
of nutrients for metabolic waste and appropriate gas exchange
in the culture system. Fresh medium was replenished by 65%
of the total vessel volume each 20 to 24 hours. As metabolic
requirements increased, fresh medium was supplemented with an
15 additional I00 mg/dl of glucose. Viable cocultures grown in
the RWVs were harvested over periods up to 45 days and
prepared for various assays.
The artificial organ tissue mass was produced in the RWV
in both a I:i mixture of M3:2 and MEM alpha supplemented with
20 10% fetal bovine serum (Hyclone Laboratories, Logan, UT) and
tri-sugar based media shown in Table 1 on a preferred culture
matrix of 5 mg/ml Cytodex-3 generally spherical microcarriers
(Pharmacia, LKB). The three dimensional tissue cultures
grown in the M3:2 and MEM media attained cell densities of
25 2.3-3.2 X l0 s cells/ml and although the cultures did not
reach plateau phase, suggesting the potential for continued
growth, the epithelial cell contingent exhibited signs of
considerable stress while the mesenchymal cells proliferated
well.
30 The preferred tri-sugar based media was found to meet
the growth requirements without the need for multiple growth
19
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factors and supplements. The cultures in the tri-sugar based
media produced slightly higher average cell densities, 4.6 to
6.2 x I0 _ cells/ml as compared to the M3:2 and MEM media
which exhibited cell densities of 2.5-3.2 x i0 _ cells/ml.
The three dimensional tissue mass grown in the tri-sugar
based media exhibited an epithelial cell component which
appeared to proliferate in a more normal and appropriate
fashion. The cultures were not grown to the plateau phase,
indicating further capability for continued growth. The
artificial tissue did not reach maximum cell densities after
38-45 days of culture.
The tissue masses grew to relatively large sizes as com-
pared to other in vitro methods. After 300 hours of culture
the tissue/microcarrier mass was about 0.2 - 0.3cm in size
with masses increasing to about 0.4 - 0.6cm after approxi-
mately 500 hours of culture and over 0.6cm after 800 hours of
culture.
The epithelial cells and mesenchymal'cells used to seed
the cultures were immunophenotyped and compared to the three
dimensional tissue cultured in the RWV. Samples were
harvested at intervals during the culture process for
immunocytochemica! analysis. The antibodies used to immunoc-
hemically characterize the cell types are listed in Table 2
below.
2O
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TABLE 2
ANTIBODIES USED FOR IMMUNOCYTOCHEMICAL ANALYSIS
Antibody Specifici_ Dilution Source/Order No. or
Pancytokeratin
Vimentin
Factor VIII
Villin
Sucrase
Angioblasts
Laminin
Fibronectin
Proteoglycan
Collagen Type IV
prediluted
predilu_ed
prediluted
1:20
1:20
1:20
1:20
1:20
1:20
1:20
Designation
DAKO, Inc./L1824
DAKO, Inc./L1843
DAKO, Inc./LlS09
Chemicon, Temacria,
CA/MAB 1671
I
A. Elbein, UTHSCSA/YT
Accurate Chem, Wes_bu-
ry, CA/HE3-5/47
ICN, Costa Mesa, CA/69-
630
US BIOCH, Cleveland,
OH/33752
Biological Products for
Science, Oxford, UK/MCA
326
DAKO, Inc./M785
The keratin, vimentin, and Factor VIII antibodies detect
15 epithelial, fibroblastic, and endothelial cells, respec-
tively. Villin is a cytoskeletal protein only found in
epithelial cells from small intestine and colon. The
angioblast marker is present in subsets of precursor endothe-
lial cells, particularly dividing cells. Sucrase is an
20 enzyme found in the epithelial cell brush border of the small
21
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intestine. Basement membrane and extracellular matrix
components laminin, fibronectin, Collagen IV, and proteogly-
can were also assayed to determine their expression in the
artificially produced three dimensional tissues.
5 Cultured organ tissue grown on Cytodex-3 microcarriers
in the RWV were fixed in OmniFix, an alcohol-based fixative
not containing aldehydes or mercury (Xenetics Biochemic,
Tustin, CA). At all times, extreme care was taken not to
damage the delicate artificial tissue comprised of cellular
I0 material and microcarrier beads. When an abundance of beads
was present, the supernatant fluid was carefully decanted and
a sample of beads was enclosed in a biopsy bag, then placed
in a cassette to prepare a paraffin block. When bead
clusters were scarce, a Shandon Cytoblock Kit (Shandon Inc.,
15 Pittsburgh, PA) was used. Cassettes were processed in a
standard tissue processor. Five-micron sections were cut
from the paraffin-embedded tissues, deparaffinized by
standard procedures, then assayed by incubation with the test
antibodies (Table 2) followed by use of the universal
20 labeling streptavidin biotin (LSAB) kit (DAKO Inc., Carpente-
ria, CA, No. K680), which detects mouse monoclonal and rabbit
polyclonal antibodies. The immunocytophenotyping was
confirmed by one positive and two negative controls. The
positive control was normal tissue sections or normal cells
25 positive for the primary antibody used. The negative
controls were i) PBS only, to test for false binding by
"link" antibody and streptavidin, and 2) normal serum of the
same species from which the primary antibody was prepared.
Analysis by immunocytochemistry was used to confirm the
30 ability of the seed cells to produce a three dimensional
artificially produced tissue mass with functional epithelial
22
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cells and functional mesenchymal cells as well as functional
precursor endothelial cells that were not present in the seed
culture. As the culture progressed and the tissue mass grew
it included functional angiob!asts.
5 Immunophenotyping of the cell types used to seed the
coculture in the RWVconfirmed the majority of epithelial and
mesenchymal cells seeded were keratin and vimentin positive,
respectively. In addition, the epithelial cells were at
various stages of differentiation. Only a small percentage
i0 (<2%) of the cells was positive for Factor VIII, an endothe-
lial cell differentiation marker. Table 3 is a summary of
the immunochemical staining reaction of the three dimensional
tissue of the present invention. The tissue was harvested at
various intervals up to 41 days as noted in Table 3.
15 An increased percentage _ 10% of cells present in the
masses consisted of endothelial cells which were Factor VIII
positive as confirmed by immunochemistry and growing as
patches on the beads. Furthermore, a small percentage, 1-2%
of cells, showed de novo expression of the HE3 angioblast
20 antigen which was not present in the seed cultures of
mesenchymal cells confirming the presence of angioblasts in
the tissue by immunochemistry. Functional cell brush borders
were confirmed immunochemically by the presence of sucrase.
Figure 1 is a photograph of the small intestine artifi-
25 cially produced organ tissue at 200X magnification showing
the three dimensional cell aggregate generally indicated by
the arrows. Figure 2 is a photograph of the small intestine
organ tissue. The triangular markers at 2 and 4 in the
photograph are for reference on the microcarriers. A mass of
30 epithelial cells is shown at 6. Elongated mesenchymal cells
are growing on the microcarriers as shown at 8 and i0.
23
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Figure 3 is a higher magnification (500X) of the epithelial
mass shown at 6 in Figure 2. Figure 4 shows the organized
columnar epithelial cells of the small intestine organ tissue
at arrows 12 and 14. Figure 5 shows the three dimensional
organ tissue masses joined by cord-like structures of
fibroblasts (mesenchymal cells) covered by epithelial cells.
24
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I0
15
20
TABLE 3
SUMMARY OF IMML_OCHEMICAL STAINING ON TISSUE
GROWTH IN RWV*
Antibodies
Keratin
Vimentin
Factor VIII
Villin
HE3
Sucrase
Laminin
Fibronectin
Proteoglycan
Collagen
Type IV
Specificity or
Cell Stained
Epithelial, Cyto-
skeletal
Fibroblasts, some
endothelial
Endothelial
Epithelial, small
intestine
Angioblasts
Small intestine,
cell brush border
Basement membrane
Basement membrane
Extracellular
matrix
Extracellular
matrix
13
+++
++
+
+++
+
+++ ++
+ +
37 4!
++ ++
++ ++
+ + ND
*Slides were observed and scored on a relative scale as - (negative) to ++++
(maximum staining; very dark positive for >90% of the cells);
+ indicates weaker staining for -25-50% of the cells; +4- indicates moderate
staining for greater than 50-75% of the cells.
25
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Samples from the RWV cultures were taken for scanning
electron microscopy at the same times as those taken for
immunocytochemistry. After removal from the reactor vessels,
samples were washed once with CMF-PBS. The samples were
5 suspended in a buffer containing 3% glutaraldehyde and 2%
paraformaldehyde in 0.I M cacodylate buffer at pH 7.4, then
rinsed for 5 minutes with cacodylate buffer three times and
postfixed with 1% osmium tetroxide (Electron Microscopy
Sciences, Fort Washington, PA) in cacodylate buffer for !
i0 hour. Samples were then rinsed for 5 minutes with distilled
water three times and then treated for i0 minutes with
Millipore (Millipore Corp., Bedford, MA) (0.2 _) filtered,
saturated solution of thiocarbohydrazide (Electron Microscopy
Sciences), then washed for 5 minutes with distilled water
five times and fixed with 1% buffered osmium tetroxide for i0
minutes. This last step was necessary to prevent the
microcarriers from collapsing. Samples were then rinsed with
distilled water three times and dehydrated with increasing
concentrations of EtOH followed by three changes in absolute
methanol. After transfer to i, i, I, 3, 3, 3-hexamethyldisi-
lazane (HMDS) (Electron Microscopy Sciences) samples were
allowed to soak for I0 minutes, drained, and air dried
overnight. Dried samples were sprinkled with a thin layer of
silver paint on a specimen stub, dried, coated by vacuum
evaporation with platinum-palladium alloy, and then examined
in the JEOL T330 Scanning electron microscope at an acceler-
ating voltage of 5 to 10 kV.
Micrographs taken of 6- to 7-day cocultures showed
partial coverage of the microcarriers by normal small
intestine mesenchymal cells. Additionally, large developing
masses of small intestine epithelium were evident, growing on
15
2O
25
3O
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the microcarrier beadpacks. Samples harvested at approxi-
mately 12 days of culture contained small microcarrier packs
which were totally engulfed in proliferating small intestine
epithelium. Micrographs of samples at 13 days displayed
large tissue-like masses that were entirely covered with
small intestine epithelium grown on a base layer of mesenchy-
mal cells. Areas of organized columnar epithelium were
prominent. As the cultures matured into mid- and late-stage
cultures, extremely complex tissue-like masses comprised of
mesenchymal and epithelial cells were seen from approximately
16 days of culture until termination at 41 days. These
tissues were assembled from smaller masses which were joined
by cord-like structures of fibroblasts and covered by
epithelial cells several layers deep. In addition, available
microcarriers were drawn to the surface of these large masses
which were approximately 0.3 to 0.5 cm in diameter. Finally,
columnar epithelium was observed to be growing even in the
recessed areas of the microcarrier bead packs.
The artificially produced mammalian structural tissue
was generated from normal mouse embryonic femurs. The fetal
cells are a mixture of chondrocytes and stromal cells. The
cells were placed in a standard media commonly designated as
CMRL 1066 (Gibco Labs) containing 10% Fetal Bovine Serum.
The cells were disassociated by standard enzymatic digestion.
The single cells produced by enzymatic digestion were washed
several times in PBS and transferred into a culture vessel
with fluid culture media. The preferred culture vessel is
described in U. S. Patent No. 5,026,650 and referenced above.
The vessel was steam sterilized by autoclaving at standard
temperature and pressure prior to transfer of the cells.
27
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A preferred culture matrix of generally spherical micro-
carrier Cytodex-3 beads were transferred into the culture
vessel. The approximate total cell inoculum was 132,000,000
at a ratio of 30 cells per Cytodex-3 microcarrier bead. The
5 bead concentration of the vessel was i0 mg/ml (4000
beads/mg). The culture media in the vessel was CMRL 1066
with ascorbic acid 10mg/ml added.
Microgravity conditions were simulated in culture vessel
as described and referenced herein. The vessel provided the
i0 quiescent well-perfused environment for maintenance of cell
surface receptors and undisturbed cell-to-cell co-location.
Co-location is important for autocrine-paracrine factor
formation and exchange between cellular types, and nurturing
of differentiation with consequential matrix deposition. The
15 cells were cultured for up to 65 days. The tissue masses
grew to at least 0.4cm in length after i000 hours of culture.
The development of normal cartilage tissue was evidenced by
normal morphology of the chondrocyte and stromal cell
formation and cartilagineous tissue substructures. Also,
20 tissue with calcification was produced. Also, proteoglycan
deposition was identified. The normal pattern of Type II
collagen deposition followed by down regulation of Type II
collagen deposition and enhanced formation of Type IX and
Type X collagen was observed.
25 Photographs taken during the culture period of the
structural cells show the growth and normal development of
the tissue. Figure 6 is a micrograph taken at 500X magni-
fication at 300 to 600 hours of culture of normal fetal mouse
chondrocytes. The cells grew around the generally spherical
30 microcarriers. Figure 7 is a higher magnification showing
preliminary calcification at the arrow 20. Figures 8 and 9
28
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were taken after 900 to ii00 hours of culture with differen-
tiated fibroblastic chondrocytes shown in Fig. 9 at 22.
Also, stromal cells are show in Fig. 9 at 24.
The artificially produced blood tissue can be made from
5 human bone marrow samples or other sources of mammalian
origin. Human bone marrow samples are obtained by standard
clinical techniques under aseptic conditions. In general, a
bone marrow tool is used to puncture the bone and obtain a
bone marrow sample that is fully inclusive of normal constit-
i0 uents. The normal constituents will include, but are not
limited to: pleuripotential stem cells, fully maturated
white blood cells and red blood cells, stromal components,
and cells in intermediate stages of maturation.
Laboratory animals such as mice can be used as a source
15 of bone marrow for selected studies. After sacrificing mice,
the femur and tibia are removed and placed in 1 X Calcium-and
Magnesium-free PBS with 200 _g/ml pen-strep. Muscle is
removed and endcaps of the bones are cut. With a syringe and
26G needle, the bone is flushed with cold complete growth
20 medium known to those skilled in the art such as CMRL 1066.
Cells are then poured through collector screens to remove
large pieces of tissue and suspended cells are placed in 50-
cc sterile tubes on cold complete growth medium. Cells are
washed and centrifuged three times to insure no contamina-
25 tion. Cells are not treated with any reagent to remove red
blood cells.
The preferred culture vessel is described in U.S. Patent
No. 5,026,650 previously cited and incorporated by reference
herein. A fluid culture media is introduced into the
30 sterilized vessel. A preferred fluid culture media is a
29
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standard tissue culture media commonly designated as RPMI-
1640 (available from Gibco and other sources).
The sterile bone marrow cells are then transferred to
fluid culture medium and suspended. Suspended cells are
5 transferred, at approximate densities of 1 X 106 cells/ml, to
the culture vessel. Various cell matrices can be used. The
collected bone marrow cells can be encased in stromal-like
matrices. The matrices can be disc-shaped. Other matrices
are generally known can be used including, but are not
i0 limited to, collagen matrices of Type I rat tail collagen or
other biopolymeric matrices. The biopolybers used can be
biodegradable such as suture materials. Cross-linked
polymers such as collagen, fibronectin and mixtures thereof
may be used. These matrices may have spherical diameters
15 ranging from 1 millimeter to i0 millimeters and include the
necessary cellular constituents to facilitate primary bone
marrow culture. Cytodex-3 microcarriers can be introduced
into the vessel at a density of 5 mg/ml. Bone marrow cells
contained in the matrix or supported in suspension are
20 cultured at microgravity conditions and mass transfer as
described herein and the incorporated references.
Early in the initiation it is preferable that the cells
are allowed to grow and metabolize without sampling interrup-
tion. The first sampling may begin one to seven days after
25 inoculation. Consequently, cellular aggregates are not
disturbed and bone marrow growth factors are not diluted by
media repletion. After the lag phase, media repletion is
based upon requirements as previously described. Cellular
phenotyping is carried out by flow cytometry and light
30 microscopy.
3O
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Figure i0 is a schematic drawing of the bone marrow cell
production. The disc-shaped culture matrices are shown at
30, 32 and 34. The bone marrow cells are shown as circular
figures at 36, 38 and 40. The arrows with the GF generally
5 indicate the excretion of growth factors from the normal bone
marrow cells that enhance tissue growth in the culture
system.
In the case of preparing bone marrow for recipients,
volumes are expanded as cellular densities or metabolic
i0 requirements dictate. The limited parameters may depend upon
the rotating vessel's ability to suspend large aggregates, in
which case if unable to suspend large aggregates, smaller
aggregates would be distributed through several vessels. If
the metabolic requirements were such that mass transfer of
15 oxygen and removal of carbon dioxide were not sufficient to
maintain cellular growth and expansion, then cells would be
aliquoted into additional vessels.
The examples included are not intended to limit the
scope of the present invention. Normal mammalian cells have
20 been cultured to produce aggregates of cells of three
dimensional tissue masses. Other substitutions, modifica-
tions and variations are apparent to those skilled in the art
without departing from the disclosure and scope of the
invention.
31
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ABSTRACTOF THE DISCLOSURE
Normal mammalian tissue and the culturing process has
been developed for the three groups of organ, structural and
blood tissue. The cells are grown in vitro under micro-
5 gravity culture conditions and form three dimensional cells
aggregates with normal cell function. The microgravity
culture conditions may be microgravity or simulated micro-
gravity created in a horizontal rotating wall culture vessel.
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